Hepatology International

Article	Citations
The safety profile of endoscopic variceal ligation in patients with esophageal varices	120
HBV in pregnancy: time to consider tenofovir alafenamide (TAF)	101
Metabolically healthy obese and MAFLD: does weight status alone matter?	90
Platelets in acute liver failure: an innocent bystander or instigator?	86
Tenofovir alafenamide-related hyperlipidemia and cardiovascular risk	68
Diagnosis of significant liver fibrosis in patients with chronic hepatitis B using a deep learning-based data integration network	67
N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD	65
Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial	57
Defining the evaluation standards for the cholangiocytic component in cHCC-CCA: a pathology-based perspective	57
Clathrin light chain A facilitates small extracellular vesicle uptake to promote hepatocellular carcinoma progression	49
Pure laparoscopic versus open left lateral hepatectomy in pediatric living donor liver transplantation: a review and meta-analysis	47
Commentary on “Comparison of relaxed verses standard cut-offs of rotational thromboelastometry for guiding blood product use before invasive procedures in advanced cirrhosis: a randomized controlled t	46
Predictive value of soluble PD-1 for HBsAg loss in HbeAg-negative patients with chronic hepatitis B: results from a prospective study	45
Response to: “Is laparoscopic hepatectomy superior to laparotomic hepatectomy? The debate continues”	44
Methodological reflections on vasoconstrictor use in refractory ascites: bridging trial rigor and real-world relevance	44
The promise of incretin-based pharmacotherapies for metabolic dysfunction-associated fatty liver disease	43
Can living donor liver transplantation provide similar outcomes to deceased-donor liver transplantation for hepatocellular carcinoma? A systematic review and meta-analysis	41
p53 regulates glucose metabolic reprogramming in MASLD-related hepatocellular carcinoma via modulating mitochondrial pyruvate carriers	39
Liver stiffness can predict decompensation and need for beta-blockers in compensated cirrhosis: a step beyond Baveno-VI criteria	38
Antioxidant, selenium and risk of nonalcoholic fatty liver disease, more than causality	38
Exosome GLUT1 derived from hepatocyte identifies the risk of non-alcoholic steatohepatitis and fibrosis	37
Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosis	35
Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy	35
Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study	35
Impact of CT-relevant skeletal muscle parameters on post-liver transplantation survival in patients with hepatocellular carcinoma	34

The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes	34
Antibiotic prophylaxis in upper gastrointestinal bleeding with Child-Pugh A cirrhosis: need for objective infection markers and broader studies	34
Good outcomes of living donor liver transplant in primary sclerosing cholangitis: an experience from North India	34
Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets	32
Development of nomograms to predict outcomes for large hepatocellular carcinoma after liver resection	32
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis	32
Liver-derived extracellular vesicles from patients with hepatitis B virus-related acute-on-chronic liver failure impair hepatic regeneration by inhibiting on FGFR2 signaling via miR-218-5p	31
Letter to the editor: Treating portal vein thrombosis in cirrhosis: is anticoagulation therapy overestimated?	31
Targeting immuno-metabolism and anti-viral immune responses in chronic hepatitis B	31
Reply to: “developing real‑world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond”	31
Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis	30
Metabolic dysfunction-associated steatotic liver disease increases the incidence of metachronous liver metastases from TNM stage 0–II colorectal cancer	30
Prevalence and impact on the outcome of myosteatosis in patients with cirrhosis: a systematic review and meta-analysis	30
Identifying the early predictors of non-response to steroids in patients with flare of autoimmune hepatitis causing acute-on-chronic liver failure	30
Drug–drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study	30
Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures	29
Correction to: Targeting ferroptosis in hepatocellular carcinoma	29
Gut microbes associated with functional cure of chronic hepatitis B	29
The relationship between CXCR6+CD8+T cells and clinicopathological parameters in patients with primary biliary cholangitis	28
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan	27
Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain	27
Role of splenic hepatic elastography ratio in differentiating non-cirrhotic portal fibrosis and chronic liver disease in children and adolescents	27
The dynamic patterns of metabolic-associated fatty liver disease and its severity and risk of cardiovascular disease	27
Prospects for treatment of esophageal varices considering the safety of endoscopic band ligation	26
Image-matching digital macro-slide—a novel pathological examination method for microvascular invasion detection in hepatocellular carcinoma	26
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients	26
Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1–AXL signal relay in liver cancer cells	25
Methodological considerations in linking depression to metabolic dysfunction-associated steatotic liver disease: insights for future study design	25
Maternal and perinatal outcome in pregnancies complicated with portal hypertension: a systematic review and meta-analysis	25
Novel and simplified model for the precise identification of concurrent bacterial infections in patients aged 60 years and older with acute-on-chronic liver diseases: a nationwide, multicentre, prospe	25
APASL STC 2025, Istanbul	25
Fecal microbiota transplantation in alcoholic hepatitis: new treatment paradigm or a shot in the dark?	25
Metabolic dysfunction associated fatty liver disease in healthy weight individuals	25
Correction: The interplay between lymphatic system and portal hypertension: a comprehensive review	25
The impact of artificial liver support system on intestinal microbiota and serum bile acid profiles in patients with acute-on-chronic liver failure: a prospective cohort study	24
Correction: Liver transplantation for acute-on-chronic liver failure	24
Global prevalence, metabolic characteristics, and outcomes of lean-MAFLD: a systematic review and meta-analysis	24
Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study	24
MAFLD, patient-centred care, and APASL	23
The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma	23
Stage-specific impact of portal hypertension on outcomes after liver resection in hepatocellular carcinoma	23
Native liver survival with therapeutic plasma exchange in acutely decompensated hepatic Wilson Disease: revisiting the Dhawan index	23
Enhancing the understanding and management of metabolic dysfunction-associated steatotic liver disease in colorectal cancer patients: insights and future directions	23
Downregulated VISTA enhances Th17 differentiation and aggravates inflammation in patients with acute-on-chronic liver failure	23
Distinct course of portal hypertension in patients with cirrhosis with gastric variceal bleeding as their first decompensation: a propensity score-matched study	22
Correction to: Exosomal miR-200b-3p induce macrophage polarization by regulating transcriptional repressor ZEB1 in hepatocellular carcinoma	22
Liver decompensation: the yard stick that measures indications and adverse effects of human albumin infusion	22
ChIP-seq analysis found IL21R, a target gene of GTF2I–the susceptibility gene for primary biliary cholangitis in Chinese Han	22
Comment on: Low-risk individuals with primary biliary cholangitis and significant liver stiffness: prognosis and treatment	21
Diagnostic yield and novel candidate genes by next generation sequencing in 166 children with intrahepatic cholestasis	21

AARC score and urine NGAL predict terlipressin non-response and mortality in patients with acute-on-chronic liver failure	21
Low skeletal muscle mass is associated with more severe histological features of non-alcoholic fatty liver disease in male	21
Recombinant human serum albumin: a true therapeutic substitute or merely a serum level elevator?	21
The effect of transition timing of regorafenib on treatment outcomes in unresectable hepatocellular carcinoma: a real-world study	21
The association between visceral adipocyte hypertrophy and NAFLD in subjects with different degrees of adiposity	21
Sleep patterns, genetic susceptibility, and risk of cirrhosis among individuals with nonalcoholic fatty liver disease	21
Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis	20
Enhancing the prognostic value of inflammatory markers in hepatocellular carcinoma: a thoughtful discussion	20
Distinctly altered lipid components in hepatocellular carcinoma relate to impaired T cell-dependent antitumor immunity	20
Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals	19
Gender differences in non-alcoholic fatty liver disease in obese children and adolescents: a large cross-sectional study	19
Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD	19
Deep learning for prediction of hepatocellular carcinoma recurrence after resection or liver transplantation: a discovery and validation study	19
Skeletal muscle alterations indicate poor prognosis in cirrhotic patients: a multicenter cohort study in China	18
Tadalafil improves erectile dysfunction and quality of life in men with cirrhosis: a randomized double blind placebo controlled trial	18
Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients	18
Benefit of adjuvant radiotherapy for gallbladder cancer: a comparability-based meta-analysis	18
Liver fat and a perturbed metabolic milieu: a consilience of factors driving liver cancer development	18
A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma	18
Modified and alternative Baveno VI criteria based on age for ruling out high-risk varices in patients with compensated cirrhosis	17
Comments on: CT-based intratumoral and peritumoral radiomics to predict the treatment response to hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 in high-risk hepatocellular carcinoma	17
Drug-induced liver injury from herbal and dietary supplements: a problem in the East and West alike	17
Oxidative stress triggers hyperdynamic circulation via central neural activation in portal hypertensive rats	16
PIRO-CIC model can predict mortality and futility of care in critically ill cirrhosis patients in the intensive care unit	16
Commentary on “Predictive value of soluble PD-1 for HBsAg loss in HBeAg-negative chronic hepatitis B patients: a prospective study”	16
Explainable attention-enhanced heuristic paradigm for multi-view prognostic risk score development in hepatocellular carcinoma	16
Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease	16
CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway	16
PIVKA-II combined with alpha-fetoprotein for the diagnostic value of hepatic tumors in children: a multicenter, prospective observational study	16
Correction to: Linking the gut and liver: crosstalk between regulatory T cells and mucosa-associated invariant T cells	16
Diversity of the nucleic acid forms of circulating HBV in chronically infected patients and its impact on viral cycle	16
The effectiveness of combination therapy with interferon and nucleoside analogs in pediatric patients with chronic hepatitis B: a systematic review and meta-analysis	16
Integrated genomic analyses of hepatocellular carcinoma	16
Stem cells therapies for liver diseases: for current practice and future goals	16
Genetic predisposition of metabolic dysfunction-associated steatotic liver disease: a population-based genome-wide association study	16
Metabolic dysfunction-associated fatty liver disease and heavy alcohol consumption increase mortality:A nationwide study	16
Predictive models for functional cure in patients with CHB receiving PEG-IFN therapy based on HBsAg quantification through meta-analysis	16
Diet-derived antioxidants and nonalcoholic fatty liver disease: a Mendelian randomization study	16
Reduction of natural killer cells is associated with poor outcomes in patients with hepatitis B virus-related acute-on-chronic liver failure	16
Interferon therapy improves survival in patients with hepatitis B virus-related hepatocellular carcinoma after curative surgery: a meta-analysis	16
Diagnosis and management of pediatric acute liver failure: consensus recommendations of the Indian Society of Pediatric Gastroenterology, Hepatology, and Nutrition (ISPGHAN)	15
Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective	15
Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma	15
Reconsiderations for the liver donation from a living donor: addressing hepatic steatosis with weight loss preconditioning	15
Hepatitis B virus-related intrahepatic cholangiocarcinoma originates from hepatocytes	15
Consensus on the secondary prevention of primary liver cancer	15
New progress towards elimination of mother-to-child transmission of hepatitis B virus in China	15
The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion	15
Nomograms should be noted	14
Hepatic irAE, ICI continuation, and survival: need for robust evidence beyond initial observations	14
Global burden of cirrhosis and liver cancer due to alcohol: the past, present, and the future	14
Gut-microbiome composition and function in progression of alcohol-associated liver disease: going beyond western experiences	14
Metabolic implications of tenofovir alafenamide in chronic hepatitis B: a commentary on cardiovascular and lipid risks	14
Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort	14
Reply to Letter to the Editor “Hepatic irAE, ICI continuation, and survival: need for robust evidence beyond initial observations”	14
Editorial: The safety profile of endoscopic variceal ligation in patients with esophageal varices. Authors’ reply	14
Predictive power of portal pressure gradient remeasured shortly after transjugular intrahepatic portosystemic shunt	14
miR-98-5p as a novel biomarker suppress liver fibrosis by targeting TGFβ receptor 1	14
Reply to: The best predictive model for post-SVR HCC: can it be universal?	13
Global, regional, and national burdens of cirrhosis in children and adolescents aged under 19 years from 1990 to 2019	13
Clinical practice guidelines on hemochromatosis: Asian Pacific Association for the Study of the Liver	13
Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment	13
Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease	13
Correction to: Complementary role of peripheral and central autonomic nervous system on insulin-like growth factor-1 activation to prevent fatty liver disease	13
Refining meta-analyses in advanced biliary tract cancer	13
Acute variceal bleeding portends poor outcomes in patients with acute-on-chronic liver failure: a propensity score matched study from the APASL ACLF Research Consortium (AARC)	13
Influence of shunt occlusion on liver volume and functions in hyperammonemic cirrhosis patients having large porto-systemic shunts: a randomized control trial	13
Correction to: Infuence of shunt occlusion on liver volume and functions in hyperammonemic cirrhosis patients having large porto-systemic shunts: a randomized control trial	13
Comments on: Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis	13
Carbohydrate-deficient transferrin is a sensitive marker of alcohol consumption in fatty liver disease	13
Low platelets: a new and simple prognostic marker for patients with hepatitis E virus-related acute liver failure	13
Characteristics of microbiome-derived metabolomics according to the progression of alcoholic liver disease	13
Effects of antiviral therapy and drug withdrawal on postpartum hepatitis in pregnant women with chronic HBV infection	12
Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes	12
Comparison of the prognostic models for mortality in idiosyncratic drug-induced liver injury	12
Response to Letter to Editor: “Systemic inflammation and prognosis in HCC: a closer look”	12
The upregulation of Annexin A2 by TLR4 pathway facilitates lipid accumulation and liver injury via blocking AMPK/mTOR-mediated autophagy flux during the development of non-alcoholic fatty liver diseas	12
Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma	12
Expanding treatment indications in chronic hepatitis B: Should we treat all patients?	12
How non-alcoholic fatty liver disease and cirrhosis affect the heart	12

Autophagy and extracellular vesicles in the liver endothelium: friends or foes?	12
Safety of right liver donation after improving steatosis through weight loss in living donors: a retrospective study	12
Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period	12
Development of an intervention system for linkage-to-care and follow-up for hepatitis B and C virus carriers	12
Exosomal miR-200b-3p induce macrophage polarization by regulating transcriptional repressor ZEB1 in hepatocellular carcinoma	12
Comparison of relaxed verses standard cut-offs of rotational thromboelastometry for guiding blood product use before invasive procedures in advanced cirrhosis: a randomized controlled trial	12
Developing real-world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond	12
Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure	11
The causes of death in patients with nonalcoholic steatohepatitis following liver transplantation stratified using pre-liver transplant BMI	11
Impact of plasma exchange on bilirubin reduction and neurological impairment in infantile acute liver failure	11
Efficacy and safety of precision-guided transjugular extrahepatic portosystemic shunt (TEPS) in the management of cavernous transformation of the portal vein with portal hypertension: a case series	11
Characteristics and long-term mortality of patients with non-MAFLD hepatic steatosis	11
Presence of sarcopenia identifies a special group of lean NAFLD in middle-aged and older people	11
Midodrine plus propranolol: potential problems and controversies behind remarkable efficacy	11
Obesity and non-alcoholic steatohepatitis in immunotherapy for hepatocellular carcinoma	11
Impact of myosteatosis on outcomes after liver transplantation: a systematic review and meta-analysis	11
Management of spontaneous portosystemic shunts at the time of liver transplantation: treatment or observation? Results of a systematic review	11
Regarding the role of post-transplant inflammatory cytokine signature on predicting tumor recurrence after liver transplantation for hepatocellular carcinoma	11
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024	11
Synthetic miR-26a mimics delivered by tumor exosomes repress hepatocellular carcinoma through downregulating lymphoid enhancer factor 1	11
Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA	11
Complications of congenital portosystemic shunts: liver tumors are affected by shunt severity, but pulmonary and neurocognitive associations are not	11
Comments on: Addition of midodrine to albumin reduces the incidence of complications of large-volume paracentesis: an RCT comparing midodrine, terlipressin, and albumins	11
Functional cure is associated with younger age in children undergoing antiviral treatment for active chronic hepatitis B	11
Risk stratification for patients with primary biliary cholangitis: early versus advanced-stage or non-cirrhosis versus cirrhosis?	11
Management of acute variceal bleeding: updated APASL guidelines	11
Key considerations in portal vein thrombosis management	11
Liver fibrosis is associated with impaired bone mineralization and microstructure in obese individuals with non-alcoholic fatty liver disease	11
GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial	11
Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study	11
Acute kidney injury stage 1a increases mortality of patients with cirrhosis: a prospective multicenter cohort study	11
AI in fatty liver diseases: insights from recent research trends	11
Outcomes of pediatric living donor liver transplantation using steatotic grafts: expanding the donor pool for rising MASLD prevalence	10
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients	10
Enhancing the evaluation and management of MAFLD: a call for comprehensive assessments and social work integration	10
Adipokine/hepatokines profiling of fatty liver in adolescents and young adults: cross-sectional and prospective analyses of the BCAMS study	10
Identification of PANoptosis-relevant subgroups and predicting signature to evaluate the prognosis and immune landscape of patients with biliary tract cancer	10
Development and experimental verification of a prognosis model for cuproptosis-related subtypes in HCC	10
Midodrine with albumin synergy in refractory ascites management	10
Single-cell transcriptomic profiling reveals dysregulation of B-cell subset function in patients with chronic hepatitis B	10
Establishment and validation of a prognostic model for hepatitis B virus‑related acute-on-chronic liver failure patients with bacterial infection	10
Metabolic interventions improve HBV envelope-specific T-cell responses in patients with chronic hepatitis B	10
Letter: Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial	10
Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome	10
Functional B cell deficiency promotes intrahepatic HBV replication and impairs the development of anti-HBV T cell responses	10
Complementary role of peripheral and central autonomic nervous system on insulin-like growth factor-1 activation to prevent fatty liver disease	10
HBV, antivirals, and immunoglobulins after liver transplantation: all that glitters is not gold	10
Unresolved heterogeneity in hepatic irAEs: critical limitations in prognostic interpretation for ICI-treated patients	10
MAFLD as part of systemic metabolic dysregulation	10
Consensus on the tertiary prevention of primary liver cancer	10
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma	10
Is laparoscopic hepatectomy superior to laparotomic hepatectomy? The debate continues	10
Lymphatic drainage dysfunction via narrowing of the lumen of cisterna chyli and thoracic duct after luminal dilation	10
Comparison of diagnostic criteria for fatty liver disease in assessing cardiac dysfunction: a cross-sectional study	9
Effect of diabetes on mortality and liver transplantation in alcoholic liver cirrhotic patients with acute decompensation	9
Integrating single-cell and bulk RNA sequencing reveals CK19 + cancer stem cells and their specific SPP1 + tumor-associated macrophage niche in HBV-related hepatocellular carcinoma	9
Methodological considerations for recombinant human serum albumin clinical translation	9
Treating extrahepatic portal-vein obstruction with cavernoma using radiological interventions: pushing the boundaries	9
Alcohol-related hepatitis admissions decline in 2021 after a 2020 surge attributed to the COVID-19 pandemic	9
Epidemiology and outcomes of primary sclerosing cholangitis: an Australian multicentre retrospective cohort study	9
Inflammation of the liver, HCC development and HCC establishment	9
Children’s hepatoblastoma: gender and infant age demand focus in the global burden of disease study 2021	9
Is lenvatinib in combination with transarterial chemoembolization benefit for unresectable hepatocellular carcinoma (uHCC)? The age interference needs to be eliminated	9
Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines	9
Response to: comment on “Stage-specific impact of portal hypertension on outcomes after liver resection in hepatocellular carcinoma”	9
Incidence, risk factors, and outcomes of acute liver injury in hospitalized adults with acute kidney injury: a large multicenter study	9
Burden, trends, and predictions of liver cancer in China, Japan, and South Korea: analysis based on the Global Burden of Disease Study 2021	9
Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy	9
Albumin, filamin-A and cytokeratin 19 help distinguish intrahepatic cholangiocarcinoma from extrahepatic adenocarcinoma	9
Comments on: Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis	9
The clinical implications of pre-liver transplant diabetes on post-liver transplant outcomes in patients with NASH: analysis of the UNOS database	9
Correction: Immunosuppression in adult liver transplant recipients: a 2024 update from the Italian Liver Transplant Working Group	9
G-CSF treatment in decompensated liver disease: a double-edged sword?	8
Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population	8
Novel immune-related prognostic models for patients with hepatocellular carcinoma after curative resection	8
FXR overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in alcoholic liver disease	8
Correction to: The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study	8
Asia–Pacific association for study of liver guidelines on management of ascites in liver disease	8
Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants	8
Immunomodulation by bepirovirsen may induce killing of infected hepatocytes (B-Together study)	8
Systemic inflammatory response markers improve the discrimination for prognostic model in hepatocellular carcinoma	8
Artificial intelligence in liver imaging: methods and applications	8
A preoperative scoring system to predict lymph node metastasis in intrahepatic cholangiocarcinoma	8
Review of current and new drugs for the treatment of metabolic-associated fatty liver disease	8
Acute-on-chronic liver failure in metabolic dysfunction-associated fatty liver disease patients: a disease multiplier	8
Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn’s disease but not Ulcerative Colitis: a prospective cohort study	8
Performance of the AASLD, EASL, and APASL Clinical Practice Guidelines in"grey zone"stages of Chinese patients with chronic hepatitis B	8
Delicate and thin fibrous septa indicate a regression tendency in metabolic dysfunction-associated steatohepatitis patients with advanced fibrosis	8
MAFLD but not MASLD increases risk of all-cause mortality in regional Australia, with components of metabolic syndrome exacerbating factors: 20 year longitudinal, cohort study	8
Prognosis factors of predicting survival in spontaneously ruptured hepatocellular carcinoma	8
Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives	8
Chinese guidelines on the management of ascites in cirrhosis	8
Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure	8
Non-invasive evaluation of NAFLD and the contribution of genes: an MRI-PDFF-based cross-sectional study	7
Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma	7